Literature DB >> 10319241

Therapeutic potential of nerve growth factors in Parkinson's disease.

T J Collier1, C E Sortwell.   

Abstract

Parkinson's disease (PD) is a neurodegenerative syndrome which primarily affects dopamine-producing neurons of the substantia nigra, resulting in poverty and slowness of movement, instability of gait and posture, and tremor at rest in individuals with the disease. While symptoms of the disease can be effectively managed for several years with available drugs, the syndrome is progressive and the efficacy of standard drugs wanes with time. One experimental approach to therapy is to use natural and synthetic molecules which promote survival and growth of dopaminergic neurons, so-called 'neurotrophic factors', to stabilise the diminishing population of dopaminergic neurons and stimulate compensation and growth in these cells. In this review, we examine the available evidence on 29 molecules with neurotrophic properties for dopaminergic neurons. The properties of these molecules provide ample reasons for optimism that a neurotrophic strategy can be developed that would provide a significant treatment option for patients with PD. While the search continues for even more specific, potent and long lasting agents, the single greatest challenge is the development of techniques for targeted delivery of these molecules.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10319241     DOI: 10.2165/00002512-199914040-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  208 in total

1.  Neocortical cell counts in normal human adult aging.

Authors:  R D Terry; R DeTeresa; L A Hansen
Journal:  Ann Neurol       Date:  1987-06       Impact factor: 10.422

Review 2.  Functions of brain-derived neurotrophic factor, insulin-like growth factor-I and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons.

Authors:  K D Beck
Journal:  Prog Neurobiol       Date:  1994-12       Impact factor: 11.685

3.  GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET.

Authors:  J Opacka-Juffry; S Ashworth; S P Hume; D Martin; D J Brooks; S B Blunt
Journal:  Neuroreport       Date:  1995-12-29       Impact factor: 1.837

4.  Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro.

Authors:  N Nakao; P Brundin; K Funa; O Lindvall; P Odin
Journal:  Brain Res Dev Brain Res       Date:  1995-12-21

5.  Carrier mediated delivery of NGF: alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors.

Authors:  C Bäckman; G M Rose; R T Bartus; B J Hoffer; E J Mufson; A C Granholm
Journal:  J Comp Neurol       Date:  1997-10-13       Impact factor: 3.215

6.  GM1 ganglioside improves dopaminergic markers of rat mesencephalic cultures treated with MPP+.

Authors:  A Dalia; N H Neff; M Hadjiconstantinou
Journal:  J Neurosci       Date:  1993-07       Impact factor: 6.167

7.  Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

Authors:  D L Choi-Lundberg; Q Lin; T Schallert; D Crippens; B L Davidson; Y N Chang; Y L Chiang; J Qian; L Bardwaj; M C Bohn
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

8.  Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment.

Authors:  M Hadjiconstantinou; N H Neff
Journal:  Eur J Pharmacol       Date:  1990-05-31       Impact factor: 4.432

9.  GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

Authors:  C M Kearns; D M Gash
Journal:  Brain Res       Date:  1995-02-20       Impact factor: 3.252

10.  Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3.

Authors:  B Knüsel; J W Winslow; A Rosenthal; L E Burton; D P Seid; K Nikolics; F Hefti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more
  24 in total

Review 1.  Neuroprotection in Parkinson's disease: an elusive goal.

Authors:  William C Koller; Maria G Cersosimo
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

2.  Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.

Authors:  Sara E Gombash; Jack W Lipton; Timothy J Collier; Lalitha Madhavan; Kathy Steece-Collier; Allyson Cole-Strauss; Brian T Terpstra; Anne L Spieles-Engemann; Brian F Daley; Susan L Wohlgenant; Valerie B Thompson; Fredric P Manfredsson; Ronald J Mandel; Caryl E Sortwell
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

3.  Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation.

Authors:  T J Collier; C E Sortwell; B F Daley
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

4.  BDNF in the Aged Brain: Translational Implications for Parkinson's Disease.

Authors:  N M Mercado; T J Collier; C E Sortwell; K Steece-Collier
Journal:  Austin Neurol Neurosci       Date:  2017-09-19

5.  Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.

Authors:  Stephane Palfi; Liza Leventhal; Yaping Chu; Shuang Y Ma; Marina Emborg; Roy Bakay; Nicole Déglon; Philippe Hantraye; Patrick Aebischer; Jeffrey H Kordower
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

6.  Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons.

Authors:  Brian T Terpstra; Timothy J Collier; Deanna M Marchionini; Nathan D Levine; Katrina L Paumier; Caryl E Sortwell
Journal:  J Neurosci Methods       Date:  2007-07-01       Impact factor: 2.390

7.  Future of cell and gene therapies for Parkinson's disease.

Authors:  Ole Isacson; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

8.  Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease.

Authors:  Merav Bahat-Stroomza; Yael Barhum; Yossef S Levy; Olga Karpov; Shlomo Bulvik; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2009-01-06       Impact factor: 3.444

9.  Decreased expression of ErbB4 and tyrosine hydroxylase mRNA and protein in the ventral midbrain of aged rats.

Authors:  J W Dickerson; A M Hemmerle; S Numan; K H Lundgren; K B Seroogy
Journal:  Neuroscience       Date:  2009-06-06       Impact factor: 3.590

Review 10.  Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies.

Authors:  Emilio Fernandez-Espejo
Journal:  Mol Neurobiol       Date:  2004-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.